KAPA Kairos Pharma, Ltd.
Kairos Pharma, Ltd. (KAPA) is expected to report earnings on November 11, 2026, before the market open. The consensus earnings estimate is a loss of $0.09 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -3.4% since its last earnings release on August 12, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Kairos Pharma, Ltd.
Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company. It focused on developing a diversified pipeline of cutting-edge oncology therapeutics born from structural biology to reverse cancer drug resistance and the inhibitory effects of cancer on the immune system. Kairos Pharma Ltd. is based in Los Angeles, California.
Sector
Healthcare
Industry
Biotechnology